Proof of concept has been demonstrated for a modern and safe immuno-nanotherapy for prostate cancer in a study published in Experimental & Molecular Medicine. These results provide the possibility of a novel, effective treatment strategy for prostate cancer.

Using a microfluidic device, the investigators designed and synthesized a nonimmunogenic biocompatible cationic lipid nanocomplex coated with PEG (NxP). These nanoliposomes were loaded with a Cas9 guide RNA–human IL-30 complex (to delete IL30, which is known to have tumour-promoting potential and is highly expressed in prostate cancer) and then conjugated with antihuman prostate cancer-specific prostate stem cell antigen (PSCA) antibodies. These immunoliposomes are called Cas9gRNA-hIL30-hPSCA NxPs.

在《实验与分子医学》上发表的一项研究中，已经证明了一种现代且安全的前列腺癌免疫纳米疗法的概念验证。这些结果为前列腺癌提供了一种新颖、有效的治疗策略的可能性。

使用微流控装置，研究人员设计并合成了一种包被 PEG （NxP） 的非免疫原性生物相容性阳离子脂质纳米复合物。这些纳米脂质体加载了 Cas9 向导 RNA-人 IL-30 复合物（以删除 IL30，已知 IL30 具有促瘤潜力并在前列腺癌中高度表达），然后与抗人前列腺癌特异性前列腺干细胞抗原 （PSCA） 抗体偶联。这些免疫脂质体称为 Cas9gRNA-hIL30-hPSCA NxPs。